ID   MPIP1_HUMAN             Reviewed;         524 AA.
AC   P30304; Q8IZH5; Q96IL3; Q9H2F2;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   10-MAY-2017, entry version 171.
DE   RecName: Full=M-phase inducer phosphatase 1;
DE            EC=3.1.3.48;
DE   AltName: Full=Dual specificity phosphatase Cdc25A;
GN   Name=CDC25A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLY-182.
RX   PubMed=1836978; DOI=10.1016/0092-8674(91)90294-9;
RA   Galaktionov K.I., Beach D.;
RT   "Specific activation of cdc25 tyrosine phosphatases by B-type cyclins:
RT   evidence for multiple roles of mitotic cyclins.";
RL   Cell 67:1181-1194(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Varmeh-Ziaie S., Manfredi J.J.;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-88.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 37-234 (ISOFORM 2).
RX   PubMed=11139144; DOI=10.1078/0171-9335-00115;
RA   Wegener S., Hampe W., Herrmann D., Schaller H.C.;
RT   "Alternative splicing in the regulatory region of the human
RT   phosphatases CDC25A and CDC25C.";
RL   Eur. J. Cell Biol. 79:810-815(2000).
RN   [6]
RP   INTERACTION WITH CHEK2, PHOSPHORYLATION AT SER-124 BY CHEK2, AND
RP   MUTAGENESIS OF SER-124.
RX   PubMed=11298456; DOI=10.1038/35071124;
RA   Falck J., Mailand N., Syljuaasen R.G., Bartek J., Lukas J.;
RT   "The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant
RT   DNA synthesis.";
RL   Nature 410:842-847(2001).
RN   [7]
RP   UBIQUITINATION BY THE APC/C UBIQUITIN LIGASE COMPLEX, DOMAIN KEN BOX
RP   MOTIF, AND MUTAGENESIS OF 141-LYS--ASN-143.
RX   PubMed=12234927; DOI=10.1093/emboj/cdf491;
RA   Donzelli M., Squatrito M., Ganoth D., Hershko A., Pagano M.,
RA   Draetta G.F.;
RT   "Dual mode of degradation of Cdc25 A phosphatase.";
RL   EMBO J. 21:4875-4884(2002).
RN   [8]
RP   PHOSPHORYLATION AT SER-124, AND MUTAGENESIS OF SER-124.
RX   PubMed=12399544; DOI=10.1073/pnas.182557299;
RA   Zhao H., Watkins J.L., Piwnica-Worms H.;
RT   "Disruption of the checkpoint kinase 1/cell division cycle 25A pathway
RT   abrogates ionizing radiation-induced S and G2 checkpoints.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14795-14800(2002).
RN   [9]
RP   PHOSPHORYLATION AT SER-124; SER-178; SER-279 AND SER-293, AND
RP   MUTAGENESIS OF SER-124; SER-178; SER-279 AND SER-293.
RX   PubMed=12676583; DOI=10.1016/S1535-6108(03)00048-5;
RA   Soerensen C.S., Syljuaesen R.G., Falck J., Schroeder T.,
RA   Roennstrand L., Khanna K.K., Zhou B.-B., Bartek J., Lukas J.;
RT   "Chk1 regulates the S phase checkpoint by coupling the physiological
RT   turnover and ionizing radiation-induced accelerated proteolysis of
RT   Cdc25A.";
RL   Cancer Cell 3:247-258(2003).
RN   [10]
RP   INTERACTION WITH BTRC; CUL1 AND FBXW11, PHOSPHODEGRON MOTIF,
RP   PHOSPHORYLATION AT SER-76 AND SER-124, UBIQUITINATION, AND MUTAGENESIS
RP   OF SER-76; SER-79; ASP-81 AND SER-82.
RX   PubMed=14681206; DOI=10.1101/gad.1157503;
RA   Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J.,
RA   Harper J.W.;
RT   "SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A
RT   protein phosphatase.";
RL   Genes Dev. 17:3062-3074(2003).
RN   [11]
RP   PHOSPHORYLATION, AND MUTAGENESIS OF CYS-431.
RX   PubMed=12676925; DOI=10.1074/jbc.M300229200;
RA   Xiao Z., Chen Z., Gunasekera A.H., Sowin T.J., Rosenberg S.H.,
RA   Fesik S., Zhang H.;
RT   "Chk1 mediates S and G2 arrests through Cdc25A degradation in response
RT   to DNA-damaging agents.";
RL   J. Biol. Chem. 278:21767-21773(2003).
RN   [12]
RP   PHOSPHORYLATION AT SER-76; SER-124 AND SER-178, AND MUTAGENESIS OF
RP   SER-76; SER-124 AND SER-178.
RX   PubMed=12759351; DOI=10.1074/jbc.M302704200;
RA   Hassepass I., Voit R., Hoffmann I.;
RT   "Phosphorylation at serine 75 is required for UV-mediated degradation
RT   of human Cdc25A phosphatase at the S-phase checkpoint.";
RL   J. Biol. Chem. 278:29824-29829(2003).
RN   [13]
RP   INTERACTION WITH CCNB1 AND YWHAE, PHOSPHORYLATION AT SER-178 AND
RP   THR-507, AND MUTAGENESIS OF SER-178; CYS-431; THR-507; LYS-514 AND
RP   ARG-520.
RX   PubMed=14559997; DOI=10.1128/MCB.23.21.7488-7497.2003;
RA   Chen M.-S., Ryan C.E., Piwnica-Worms H.;
RT   "Chk1 kinase negatively regulates mitotic function of Cdc25A
RT   phosphatase through 14-3-3 binding.";
RL   Mol. Cell. Biol. 23:7488-7497(2003).
RN   [14]
RP   INTERACTION WITH PIM1.
RX   PubMed=16356754; DOI=10.1016/j.biocel.2005.10.010;
RA   Bachmann M., Kosan C., Xing P.X., Montenarh M., Hoffmann I., Moroy T.;
RT   "The oncogenic serine/threonine kinase Pim-1 directly phosphorylates
RT   and activates the G2/M specific phosphatase Cdc25C.";
RL   Int. J. Biochem. Cell Biol. 38:430-443(2006).
RN   [15]
RP   PHOSPHORYLATION AT SER-79; SER-82 AND SER-88.
RX   PubMed=19734889; DOI=10.1038/ncb1969;
RA   Melixetian M., Klein D.K., Soerensen C.S., Helin K.;
RT   "NEK11 regulates CDC25A degradation and the IR-induced G2/M
RT   checkpoint.";
RL   Nat. Cell Biol. 11:1247-1253(2009).
RN   [16]
RP   PHOSPHORYLATION AT SER-82 AND SER-88.
RX   PubMed=20090422; DOI=10.4161/cc.9.3.10513;
RA   Soerensen C.S., Melixetian M., Klein D.K., Helin K.;
RT   "NEK11: linking CHK1 and CDC25A in DNA damage checkpoint signaling.";
RL   Cell Cycle 9:450-455(2010).
RN   [17]
RP   DEUBIQUITINATION BY USP17L2.
RX   PubMed=20228808; DOI=10.1038/ncb2041;
RA   Pereg Y., Liu B.Y., O'Rourke K.M., Sagolla M., Dey A., Komuves L.,
RA   French D.M., Dixit V.M.;
RT   "Ubiquitin hydrolase Dub3 promotes oncogenic transformation by
RT   stabilizing Cdc25A.";
RL   Nat. Cell Biol. 12:400-406(2010).
RN   [18]
RP   PHOSPHORYLATION AT SER-513 AND SER-519 BY PLK3, UBIQUITINATION, AND
RP   MUTAGENESIS OF SER-513 AND SER-519.
RX   PubMed=21376736; DOI=10.1016/j.mrfmmm.2011.02.006;
RA   Myer D.L., Robbins S.B., Yin M., Boivin G.P., Liu Y., Greis K.D.,
RA   Bahassi el M., Stambrook P.J.;
RT   "Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA
RT   damage but is not sufficient to produce tumors.";
RL   Mutat. Res. 714:1-10(2011).
RN   [19]
RP   INTERACTION WITH HSP90AB1.
RX   PubMed=22843495; DOI=10.1093/hmg/dds303;
RA   Giessrigl B., Krieger S., Rosner M., Huttary N., Saiko P., Alami M.,
RA   Messaoudi S., Peyrat J.F., Maciuk A., Gollinger M., Kopf S.,
RA   Kazlauskas E., Mazal P., Szekeres T., Hengstschlaeger M., Matulis D.,
RA   Jaeger W., Krupitza G.;
RT   "Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A
RT   degradation and cell-cycle attenuation in pancreatic carcinoma
RT   cells.";
RL   Hum. Mol. Genet. 21:4615-4627(2012).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-107 AND SER-321, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 336-496.
RX   PubMed=9604936; DOI=10.1016/S0092-8674(00)81190-3;
RA   Fauman E.B., Cogswell J.P., Lovejoy B., Rocque W.J., Holmes W.,
RA   Montana V.G., Piwnica-Worms H., Rink M.J., Saper M.A.;
RT   "Crystal structure of the catalytic domain of the human cell cycle
RT   control phosphatase, Cdc25A.";
RL   Cell 93:617-625(1998).
CC   -!- FUNCTION: Tyrosine protein phosphatase which functions as a
CC       dosage-dependent inducer of mitotic progression. Directly
CC       dephosphorylates CDK1 and stimulates its kinase activity. Also
CC       dephosphorylates CDK2 in complex with cyclin E, in vitro.
CC   -!- CATALYTIC ACTIVITY: Protein tyrosine phosphate + H(2)O = protein
CC       tyrosine + phosphate.
CC   -!- ENZYME REGULATION: Stimulated by B-type cyclins. Stimulated by
CC       PIM1-mediated phosphorylation.
CC   -!- SUBUNIT: Interacts with CCNB1/cyclin B1. Interacts with YWHAE/14-
CC       3-3 epsilon when phosphorylated. Interacts with CUL1 specifically
CC       when CUL1 is neddylated and active. Interacts with BTRC/BTRCP1 and
CC       FBXW11/BTRCP2. Interactions with CUL1, BTRC and FBXW11 are
CC       enhanced upon DNA damage. Interacts with PIM1. Interacts with
CC       CHEK2; mediates CDC25A phosphorylation and degradation in response
CC       to infrared-induced DNA damages. Interacts with HSP90AB1; prevents
CC       heat shock-mediated CDC25A degradation and contributes to cell
CC       cycle progression (PubMed:22843495). {ECO:0000269|PubMed:11298456,
CC       ECO:0000269|PubMed:14559997, ECO:0000269|PubMed:14681206,
CC       ECO:0000269|PubMed:16356754, ECO:0000269|PubMed:22843495}.
CC   -!- INTERACTION:
CC       P04049:RAF1; NbExp=4; IntAct=EBI-747671, EBI-365996;
CC       P31946:YWHAB; NbExp=8; IntAct=EBI-747671, EBI-359815;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-747671, EBI-347088;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=CDC25A1;
CC         IsoId=P30304-1; Sequence=Displayed;
CC       Name=2; Synonyms=CDC25A2;
CC         IsoId=P30304-2; Sequence=VSP_000860;
CC   -!- DOMAIN: The phosphodegron motif mediates interaction with specific
CC       F-box proteins when phosphorylated. Putative phosphorylation sites
CC       at Ser-79 and Ser-82 appear to be essential for this interaction.
CC       {ECO:0000269|PubMed:12234927}.
CC   -!- PTM: Phosphorylated by CHEK1 on Ser-76, Ser-124, Ser-178, Ser-279,
CC       Ser-293 and Thr-507 during checkpoint mediated cell cycle arrest.
CC       Also phosphorylated by CHEK2 on Ser-124, Ser-279, and Ser-293
CC       during checkpoint mediated cell cycle arrest. Phosphorylation on
CC       Ser-178 and Thr-507 creates binding sites for YWHAE/14-3-3 epsilon
CC       which inhibits CDC25A. Phosphorylation on Ser-76, Ser-124, Ser-
CC       178, Ser-279 and Ser-293 may also promote ubiquitin-dependent
CC       proteolysis of CDC25A by the SCF complex. Phosphorylation of
CC       CDC25A at Ser-76 by CHEK1 primes it for subsequent phosphorylation
CC       at Ser-79, Ser-82 and Ser-88 by NEK11. Phosphorylation by NEK11 is
CC       required for BTRC-mediated polyubiquitination and degradation.
CC       Phosphorylation by PIM1 leads to an increase in phosphatase
CC       activity. Phosphorylated by PLK3 following DNA damage, leading to
CC       promote its ubiquitination and degradation.
CC       {ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12399544,
CC       ECO:0000269|PubMed:12676583, ECO:0000269|PubMed:12676925,
CC       ECO:0000269|PubMed:12759351, ECO:0000269|PubMed:14559997,
CC       ECO:0000269|PubMed:14681206, ECO:0000269|PubMed:19734889,
CC       ECO:0000269|PubMed:20090422, ECO:0000269|PubMed:20228808,
CC       ECO:0000269|PubMed:21376736}.
CC   -!- PTM: Ubiquitinated by the anaphase promoting complex/cyclosome
CC       (APC/C) ubiquitin ligase complex that contains FZR1/CDH1 during G1
CC       phase leading to its degradation by the proteasome. Ubiquitinated
CC       by a SCF complex containing BTRC and FBXW11 during S phase leading
CC       to its degradation by the proteasome. Deubiquitination by
CC       USP17L2/DUB3 leads to its stabilization.
CC       {ECO:0000269|PubMed:20228808}.
CC   -!- SIMILARITY: Belongs to the MPI phosphatase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CDC25AID40004ch3p21.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/cdc25a/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81933; AAA58415.1; -; mRNA.
DR   EMBL; AY137580; AAN11305.1; -; mRNA.
DR   EMBL; AF527417; AAM77917.1; -; Genomic_DNA.
DR   EMBL; BC007401; AAH07401.1; -; mRNA.
DR   EMBL; BC018642; AAH18642.1; -; mRNA.
DR   EMBL; AF277722; AAG41884.1; -; mRNA.
DR   CCDS; CCDS2760.1; -. [P30304-1]
DR   CCDS; CCDS2761.1; -. [P30304-2]
DR   PIR; A41648; A41648.
DR   RefSeq; NP_001780.2; NM_001789.2. [P30304-1]
DR   RefSeq; NP_963861.1; NM_201567.1. [P30304-2]
DR   RefSeq; XP_011532618.1; XM_011534316.1. [P30304-1]
DR   UniGene; Hs.437705; -.
DR   PDB; 1C25; X-ray; 2.30 A; A=337-496.
DR   PDBsum; 1C25; -.
DR   ProteinModelPortal; P30304; -.
DR   SMR; P30304; -.
DR   BioGrid; 107428; 55.
DR   DIP; DIP-166N; -.
DR   IntAct; P30304; 37.
DR   MINT; MINT-124723; -.
DR   STRING; 9606.ENSP00000303706; -.
DR   BindingDB; P30304; -.
DR   ChEMBL; CHEMBL3775; -.
DR   DEPOD; P30304; -.
DR   iPTMnet; P30304; -.
DR   PhosphoSitePlus; P30304; -.
DR   BioMuta; CDC25A; -.
DR   DMDM; 50403734; -.
DR   EPD; P30304; -.
DR   MaxQB; P30304; -.
DR   PaxDb; P30304; -.
DR   PeptideAtlas; P30304; -.
DR   PRIDE; P30304; -.
DR   DNASU; 993; -.
DR   Ensembl; ENST00000302506; ENSP00000303706; ENSG00000164045. [P30304-1]
DR   Ensembl; ENST00000351231; ENSP00000343166; ENSG00000164045. [P30304-2]
DR   GeneID; 993; -.
DR   KEGG; hsa:993; -.
DR   UCSC; uc003csh.2; human. [P30304-1]
DR   CTD; 993; -.
DR   DisGeNET; 993; -.
DR   GeneCards; CDC25A; -.
DR   HGNC; HGNC:1725; CDC25A.
DR   HPA; HPA005855; -.
DR   MIM; 116947; gene.
DR   neXtProt; NX_P30304; -.
DR   OpenTargets; ENSG00000164045; -.
DR   PharmGKB; PA26259; -.
DR   eggNOG; KOG3772; Eukaryota.
DR   eggNOG; COG5105; LUCA.
DR   GeneTree; ENSGT00390000018747; -.
DR   HOGENOM; HOG000082672; -.
DR   HOVERGEN; HBG052501; -.
DR   InParanoid; P30304; -.
DR   KO; K06645; -.
DR   OMA; RGCLHSH; -.
DR   OrthoDB; EOG091G0H0D; -.
DR   PhylomeDB; P30304; -.
DR   TreeFam; TF101056; -.
DR   BRENDA; 3.1.3.48; 2681.
DR   Reactome; R-HSA-113507; E2F-enabled inhibition of pre-replication complex formation.
DR   Reactome; R-HSA-113510; E2F mediated regulation of DNA replication.
DR   Reactome; R-HSA-1538133; G0 and Early G1.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-157881; Cyclin B2 mediated events.
DR   Reactome; R-HSA-176187; Activation of ATR in response to replication stress.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69205; G1/S-Specific Transcription.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-69601; Ubiquitin Mediated Degradation of Phosphorylated Cdc25A.
DR   Reactome; R-HSA-69610; p53-Independent DNA Damage Response.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   SIGNOR; P30304; -.
DR   ChiTaRS; CDC25A; human.
DR   EvolutionaryTrace; P30304; -.
DR   GeneWiki; CDC25A; -.
DR   GenomeRNAi; 993; -.
DR   PRO; PR:P30304; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000164045; -.
DR   CleanEx; HS_CDC25A; -.
DR   ExpressionAtlas; P30304; baseline and differential.
DR   Genevisible; P30304; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0051087; F:chaperone binding; IPI:UniProtKB.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0006260; P:DNA replication; TAS:Reactome.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; TAS:UniProtKB.
DR   GO; GO:0009314; P:response to radiation; IDA:UniProtKB.
DR   Gene3D; 3.40.250.10; -; 1.
DR   InterPro; IPR000751; MPI_Phosphatase.
DR   InterPro; IPR001763; Rhodanese-like_dom.
DR   Pfam; PF06617; M-inducer_phosp; 1.
DR   Pfam; PF00581; Rhodanese; 1.
DR   PRINTS; PR00716; MPIPHPHTASE.
DR   SMART; SM00450; RHOD; 1.
DR   SUPFAM; SSF52821; SSF52821; 1.
DR   PROSITE; PS50206; RHODANESE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell cycle; Cell division;
KW   Complete proteome; Hydrolase; Mitosis; Phosphoprotein; Polymorphism;
KW   Protein phosphatase; Reference proteome; Ubl conjugation.
FT   CHAIN         1    524       M-phase inducer phosphatase 1.
FT                                /FTId=PRO_0000198641.
FT   DOMAIN      376    482       Rhodanese. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00173}.
FT   MOTIF        74     84       Phosphodegron.
FT   MOTIF       141    143       KEN box.
FT   ACT_SITE    431    431
FT   MOD_RES      76     76       Phosphoserine; by CHEK1.
FT                                {ECO:0000269|PubMed:12759351,
FT                                ECO:0000269|PubMed:14681206}.
FT   MOD_RES      79     79       Phosphoserine; by NEK11.
FT                                {ECO:0000269|PubMed:19734889}.
FT   MOD_RES      82     82       Phosphoserine; by NEK11.
FT                                {ECO:0000269|PubMed:19734889,
FT                                ECO:0000269|PubMed:20090422}.
FT   MOD_RES      88     88       Phosphoserine; by NEK11.
FT                                {ECO:0000269|PubMed:19734889,
FT                                ECO:0000269|PubMed:20090422}.
FT   MOD_RES     107    107       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     124    124       Phosphoserine; by CHEK1 and CHEK2.
FT                                {ECO:0000269|PubMed:11298456,
FT                                ECO:0000269|PubMed:12399544,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12759351,
FT                                ECO:0000269|PubMed:14681206}.
FT   MOD_RES     178    178       Phosphoserine; by CHEK1.
FT                                {ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12759351,
FT                                ECO:0000269|PubMed:14559997}.
FT   MOD_RES     279    279       Phosphoserine; by CHEK1 and CHEK2.
FT                                {ECO:0000269|PubMed:12676583}.
FT   MOD_RES     293    293       Phosphoserine; by CHEK1 and CHEK2.
FT                                {ECO:0000269|PubMed:12676583}.
FT   MOD_RES     321    321       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     507    507       Phosphothreonine; by CHEK1.
FT                                {ECO:0000269|PubMed:14559997}.
FT   MOD_RES     513    513       Phosphoserine; by PLK3.
FT                                {ECO:0000269|PubMed:21376736}.
FT   MOD_RES     519    519       Phosphoserine; by PLK3.
FT                                {ECO:0000269|PubMed:21376736}.
FT   VAR_SEQ     144    183       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11139144,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_000860.
FT   VARIANT      88     88       S -> F (in dbSNP:rs3731499).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_020932.
FT   VARIANT     182    182       R -> G (in dbSNP:rs6771386).
FT                                {ECO:0000269|PubMed:1836978}.
FT                                /FTId=VAR_023532.
FT   VARIANT     182    182       R -> W (in dbSNP:rs6771386).
FT                                /FTId=VAR_023533.
FT   MUTAGEN      76     76       S->A: Abolishes ubiquitination and
FT                                impairs CHEK1-dependent degradation
FT                                following checkpoint activation.
FT                                {ECO:0000269|PubMed:12759351,
FT                                ECO:0000269|PubMed:14681206}.
FT   MUTAGEN      79     79       S->A: Abrogates interactions with BTRC
FT                                and FBXW11 and prevents ubiquitination.
FT                                {ECO:0000269|PubMed:14681206}.
FT   MUTAGEN      81     81       D->A: Abrogates interactions with BTRC
FT                                and FBXW11 and prevents ubiquitination.
FT                                {ECO:0000269|PubMed:14681206}.
FT   MUTAGEN      82     82       S->A: Abrogates interactions with BTRC
FT                                and FBXW11 and prevents ubiquitination.
FT                                {ECO:0000269|PubMed:14681206}.
FT   MUTAGEN     124    124       S->A: Abrogates phosphorylation by CHEK2
FT                                and infrared-induced degradation.
FT                                Increases basal stability and impairs
FT                                CHEK1-dependent degradation following
FT                                checkpoint activation; when associated
FT                                with A-178; A-279 and A-293.
FT                                {ECO:0000269|PubMed:11298456,
FT                                ECO:0000269|PubMed:12399544,
FT                                ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12759351}.
FT   MUTAGEN     141    143       KEN->AAA: Prevents ubiquitination and
FT                                subsequent degradation by the APC/C
FT                                ubiquitin ligase complex.
FT                                {ECO:0000269|PubMed:12234927}.
FT   MUTAGEN     178    178       S->A: Increases basal stability and
FT                                impairs CHEK1-dependent degradation
FT                                following checkpoint activation; when
FT                                associated with A-124; A-279 and A-293.
FT                                Abrogates 14-3-3 protein binding.
FT                                {ECO:0000269|PubMed:12676583,
FT                                ECO:0000269|PubMed:12759351,
FT                                ECO:0000269|PubMed:14559997}.
FT   MUTAGEN     279    279       S->A: Increases basal stability and
FT                                impairs CHEK1-dependent degradation
FT                                following checkpoint activation; when
FT                                associated with A-124; A-178 and A-293.
FT                                {ECO:0000269|PubMed:12676583}.
FT   MUTAGEN     293    293       S->A: Increases basal stability and
FT                                impairs CHEK1-dependent degradation
FT                                following checkpoint activation; when
FT                                associated with A-124; A-178 and A-279.
FT                                {ECO:0000269|PubMed:12676583}.
FT   MUTAGEN     431    431       C->S: Abolishes phosphatase activity.
FT                                {ECO:0000269|PubMed:12676925,
FT                                ECO:0000269|PubMed:14559997}.
FT   MUTAGEN     507    507       T->A: Abrogates 14-3-3 protein binding;
FT                                increases binding to cyclin B1.
FT                                {ECO:0000269|PubMed:14559997}.
FT   MUTAGEN     513    513       S->A: Increased stability following IR
FT                                treatment. {ECO:0000269|PubMed:21376736}.
FT   MUTAGEN     513    513       S->D: Mimicks phosphorylation state,
FT                                leading to promote degradation following
FT                                IR treatment.
FT                                {ECO:0000269|PubMed:21376736}.
FT   MUTAGEN     514    514       K->L: Abrogates binding to CCNB1; when
FT                                associated with L-520.
FT                                {ECO:0000269|PubMed:14559997}.
FT   MUTAGEN     519    519       S->A: Increased stability following IR
FT                                treatment. {ECO:0000269|PubMed:21376736}.
FT   MUTAGEN     519    519       S->D: Mimicks phosphorylation state,
FT                                leading to promote degradation following
FT                                IR treatment.
FT                                {ECO:0000269|PubMed:21376736}.
FT   MUTAGEN     520    520       R->L: Abrogates binding to CCNB1; when
FT                                associated with L-514.
FT                                {ECO:0000269|PubMed:14559997}.
FT   CONFLICT      6     10       EPPHR -> SPAP (in Ref. 1; AAA58415).
FT                                {ECO:0000305}.
FT   CONFLICT    180    181       PA -> QL (in Ref. 1; AAA58415).
FT                                {ECO:0000305}.
FT   STRAND      341    344       {ECO:0000244|PDB:1C25}.
FT   HELIX       362    369       {ECO:0000244|PDB:1C25}.
FT   TURN        370    376       {ECO:0000244|PDB:1C25}.
FT   STRAND      377    384       {ECO:0000244|PDB:1C25}.
FT   HELIX       388    392       {ECO:0000244|PDB:1C25}.
FT   HELIX       405    411       {ECO:0000244|PDB:1C25}.
FT   TURN        412    414       {ECO:0000244|PDB:1C25}.
FT   STRAND      423    430       {ECO:0000244|PDB:1C25}.
FT   STRAND      432    436       {ECO:0000244|PDB:1C25}.
FT   HELIX       437    451       {ECO:0000244|PDB:1C25}.
FT   STRAND      463    466       {ECO:0000244|PDB:1C25}.
FT   HELIX       469    477       {ECO:0000244|PDB:1C25}.
FT   HELIX       478    480       {ECO:0000244|PDB:1C25}.
FT   STRAND      481    484       {ECO:0000244|PDB:1C25}.
SQ   SEQUENCE   524 AA;  59087 MW;  B2F6B792D4E6122B CRC64;
     MELGPEPPHR RRLLFACSPP PASQPVVKAL FGASAAGGLS PVTNLTVTMD QLQGLGSDYE
     QPLEVKNNSN LQRMGSSEST DSGFCLDSPG PLDSKENLEN PMRRIHSLPQ KLLGCSPALK
     RSHSDSLDHD IFQLIDPDEN KENEAFEFKK PVRPVSRGCL HSHGLQEGKD LFTQRQNSAP
     ARMLSSNERD SSEPGNFIPL FTPQSPVTAT LSDEDDGFVD LLDGENLKNE EETPSCMASL
     WTAPLVMRTT NLDNRCKLFD SPSLCSSSTR SVLKRPERSQ EESPPGSTKR RKSMSGASPK
     ESTNPEKAHE TLHQSLSLAS SPKGTIENIL DNDPRDLIGD FSKGYLFHTV AGKHQDLKYI
     SPEIMASVLN GKFANLIKEF VIIDCRYPYE YEGGHIKGAV NLHMEEEVED FLLKKPIVPT
     DGKRVIVVFH CEFSSERGPR MCRYVRERDR LGNEYPKLHY PELYVLKGGY KEFFMKCQSY
     CEPPSYRPMH HEDFKEDLKK FRTKSRTWAG EKSKREMYSR LKKL
//
